Journal of Nucleic Acids

Journal of Nucleic Acids / 2012 / Article
Special Issue

Artificially Created Nucleic Acids and Peptides/Proteins in Chemical Biology

View this Special Issue

Review Article | Open Access

Volume 2012 |Article ID 740982 | 15 pages |

Potential of Peptides as Inhibitors and Mimotopes: Selection of Carbohydrate-Mimetic Peptides from Phage Display Libraries

Academic Editor: Hiroshi Murakami
Received01 Jun 2012
Revised31 Jul 2012
Accepted02 Aug 2012
Published10 Oct 2012


Glycoconjugates play various roles in biological processes. In particular, oligosaccharides on the surface of animal cells are involved in virus infection and cell-cell communication. Inhibitors of carbohydrate-protein interactions are potential antiviral drugs. Several anti-influenza drugs such as oseltamivir and zanamivir are derivatives of sialic acid, which inhibits neuraminidase. However, it is very difficult to prepare a diverse range of sugar derivatives by chemical synthesis or by the isolation of natural products. In addition, the pathogenic capsular polysaccharides of bacteria are carbohydrate antigens, for which a safe and efficacious method of vaccination is required. Phage-display technology has been improved to enable the identification of peptides that bind to carbohydrate-binding proteins, such as lectins and antibodies, from a large repertoire of peptide sequences. These peptides are known as “carbohydrate-mimetic peptides (CMPs)” because they mimic carbohydrate structures. Compared to carbohydrate derivatives, it is easy to prepare mono- and multivalent peptides and then to modify them to create various derivatives. Such mimetic peptides are available as peptide inhibitors of carbohydrate-protein interactions and peptide mimotopes that are conjugated with adjuvant for vaccination.

1. Introduction

A variety of glycoconjugate carbohydrate structures on the cell surface are important for biological events [1]. Carbohydrate structures on the cell surface change according to cell status, for example, during development, differentiation, and malignant alteration. Several glycoconjugates, including stage-specific embryonic antigen (SSEA)-3, SSEA-4, and tumor-rejection antigen (TRA)-1-60, are used as molecular makers of pluripotency to control the quality of induced pluripotent stem (iPS) cells [2]. Carbohydrate-protein interactions are the first cell surface events in cell-cell communication, following which processes such as infection and signal transduction occur. However, the reasons for the changes in carbohydrate structures on the cell surface are not clear. In addition, most receptors for glycoconjugates have not been identified. To investigate the biological roles of carbohydrates, sets of carbohydrates and their corresponding carbohydrate-binding proteins are required.

Carbohydrate-binding proteins such as plant lectins, bacterial toxins, and anticarbohydrate antibodies are available for studying carbohydrate-protein interactions [3, 4]. However, the repertoire of carbohydrate structures recognized by these proteins is limited and insufficient to cover the majority of structures. In addition, because carbohydrates are ubiquitous components of cell membranes and bio(macro)molecules, the immune response stimulated by glycoconjugates is negligible [5, 6], that is, high affinity carbohydrate-specific IgG-isotype antibodies are not easily obtained. Even if anticarbohydrate antibodies are generated, IgG comprises no more than 28% of the antibodies (74 IgGs in a total of 268 antibodies, with the remainder being IgMs) [7]. Therefore, while anticarbohydrate antibodies of the IgG isotype are preferred for carbohydrate research, IgM-antibodies with low affinity have been often used. Moreover, obtaining pure and homogeneous carbohydrates (or glycoconjugates) is very difficult. This is because regioselective protection of the hydroxy groups of the monosaccharide is required. Programmable one-pot oligosaccharide synthesis is widely performed using protected monosaccharides and/or oligosaccharides [810]. Enzyme-catalyzed oligosaccharide synthesis has been also developed [1012]. Several oligosaccharides such as KH-1 antigen (nonasaccharide of - ), globo-H hexasaccharide, and the core pentamannosides have been prepared by automated solid-phase oligosaccharide synthesis [8]. However, due to the complicated procedures of carbohydrate preparation, a general methodology for their chemical synthesis is not yet established.

To compensate for the lack of synthetic carbohydrates and to overcome their inherent weak immunogenicity, short peptides that bind to carbohydrate-binding proteins have been identified from phage-display libraries (Figure 1). These peptides mimic carbohydrate structures [13] and are called “carbohydrate-mimetic peptides (CMPs)” or “peptide mimotopes.” It is predicted that CMPs, as well as carbohydrates, are recognized by carbohydrate-binding proteins. Small molecules such as biotin and carbohydrate mimotope (Glycotope) mimicking peptides have been frequently identified, and a number of reviews focusing on different aspects of their properties and uses have been published [1416]. In this paper, recent studies on the selection and application of CMPs are surveyed and summarized according to the classification of target carbohydrate-binding proteins.

2. Peptide Selection from Phage Display Libraries

Phage display is an efficient selection (and screening) system for the identification of target-specific peptides and proteins from a large number of candidates [2022]. A filamentous virus (M13 and fd, etc.) that infects E. coli is frequently used in phage display technology. When DNA encoding foreign sequences is inserted into the coat protein (pIII or pVIII) region in the virus genome (M13 phage vector, etc.), the corresponding sequence is fused with the coat protein of the viral particle (Figure 2(a)) [20]. The foreign sequence is “displayed” on the viral particle and is able to interact with various types of target molecules.

In the case of peptide libraries, the length of the peptides is often 5–20 amino acids. There are two types of peptide library: linear peptide libraries and cyclic peptide libraries (Figure 2(b)). The randomized region of cyclic peptide libraries is surrounded by two cysteines (e.g., CX7C) to restrict the peptide conformation via disulfide bonds. The diversity of a peptide library is often 108-109, which is sufficient to cover a combination of hexapeptide libraries (X6; 206 = 6.4 × 107). Several kinds of peptide libraries (e.g., Ph.D. Phage Display Peptide Library Kits, New England Biolabs) and customizable phage vectors (Ph.D. Peptide Display Cloning System) are commercially available.

To isolate phage clones that have high affinity for a target molecule, a set of procedures called “affinity selection (biopanning)” is performed (Figure 2(c)). First, the target molecule is incubated with the phage library in order to bind to specific peptide sequences. After removal of excess phages by washing, the bound phages are eluted by incubation with a known ligand for the target or an acidic buffer. The phages are amplified by infection of hosts (E. coli), and the phage pool is subjected to another round of biopanning. By repeating these steps, target-binding phages are enriched, and, finally, phage clones are obtained. The peptides with high affinity for the target molecule are identified by DNA sequencing of individual phage clones. Huang and coworkers established a mimotope database MimoDB ( that contains the results of biopanning experiments including the phage libraries used and the peptide sequences identified [23, 24]. This database will help in the development of therapeutic molecules and the identification of superior peptide mimotopes for vaccination.

3. CMPs against Lectins

3.1. Monosaccharide-Mimetic Peptides

Most lectins recognize monosaccharides and disaccharides [4]. Concanavalin A (ConA) is a lectin from jack-bean (Canavalia ensiformis) that binds to α-mannose (α-Man) and α-glucose (α-Glc). ConA is a famous lectin that is commercially available for the biological investigation of glycoconjugates. The first CMPs were selected from a random peptide library against ConA simultaneously by Oldenburg et al. (octapeptide library) [25] and Scott et al. (hexapeptide library) [13] (Table 1). Peptides containing the consensus sequence, Tyr-Pro-Tyr (YPY), showed high affinity for ConA with a dissociation constant ( ) of 46 μM, and the for methyl α-Man was 89 μM. The peptides are considered to mimic the structure of carbohydrates because the ConA-peptide interaction was inhibited by α-Man.

Target lectins (abbreviations)Peptide libraryPeptide motif or representative sequences (peptide name)Lectin-binding carbohydrate structuresReferencesNotes*

Concanavalin A (ConA)X8, X6YPY motifMan; Glc[13, 25, 26]Inhibition of Man binding
Griffonia simplicifolia I-B4 isolectin (GS-I-B4)X6SSLRGFGal 1-3Gal[27]Inhibition of RBC agglutination
Bandeiraea simplicifolia I-B4 isolectin (BS-I-B4)XCX15NCVSPYWCEPLAPSARAGal 1-3Gal[28]Inhibition of RBC agglutination
E-selectinX12DITWDQLWDLMKSialyl LewisX [Neu5Ac 2-3Gal 1-4(Fuc 1–3)GlcNAc][29]Inhibition of cell adhesion, reduction of neutrophil rolling, and so forth
X7IELLQAR[30]Octameric MAP, inhibition of HL-60, and B16 cell adhesion
Concanavalin A (ConA); Lens culinaris agglutinin (LCA); Pisum sativum agglutinin (PSA)X12, CX7CCNTPLTSRC; CSRILTAACMan; Glc[31]Inhibition of Man binding; docking study
Lectin from Helix pomatia (HPA)X12VQATQSNQHTPRGGGSO-linked -GalNAc; Galβ1-3GalNAc; -GlcNAc[32]Tetrameric dendrimer, stimulation of IL-8, and IL-21 secretion
Lipopolysaccharide (LPS) binding protein (LBP); CD14X12FHRWPTWPLPSP (MP12)Lipopolysaccharide[33]Inhibition of LPS-induced INF- expression
Influenza virus hemagglutinin (HA)X15ARLPRTMVHPKPAQP (s2); ARLPR [s2(1–5)]Neu5Ac 2-3Gal[17]N-stearoyl peptide; inhibition of flu infection

* RBC: red blood cell; IL: interleukin; INF: interferon.

To obtain Man/Glc-mimetic peptides, Yu et al. used three lectins, including ConA, Lens culinaris agglutinin (LCA) from lentil, and Pisum sativum agglutinin (PSA) from pea [31]. Two cyclic peptides, CNTPLTSRC and CSRILTAAC, were selected from a cyclic heptapeptide library, but these peptides did not contain the YPY motif. Docking simulation of the peptide-lectin interaction suggested that the cyclic peptides bound to an alternative binding site, not to the sugar-binding site that is recognized by YPY-containing peptides. In another screen using monosaccharide-binding lectins, Eggink and Hoober identified a GalNAc/Gal-mimetic dodecapeptide, VQATQSNQHTPR, that was selected against Helix pomatia (HPA) lectin [32]. A tetrameric dendrimer of the peptide, [(VQATQSNQHTPR)2 K]2 K, was synthesized chemically (Figure 3), which was shown to stimulate the secretion of interleukin (IL)-8 and IL-21 from human peripheral blood mononuclear cells (PBMCs).

3.2. Disaccharide-Mimetic Peptides

The Galα1-3Gal disaccharide is recognized by Griffonia simplicifolia I-B4 (GS-I-B4) and Bandeiraea simplicifolia isolectin B4 (BS-I-B4) (Figure 4). The Galα1-3Gal structure is a major carbohydrate antigen recognized by human anti-pig antibodies, and inhibitors of human natural antibodies may be useful in pig-to-human xenotransplantation. Kooyman et al. identified a peptide sequence, SSLRGF, that binds to GS-I-B4 lectin from a hexapeptide library [27]. Zhan et al. identified a peptide, NCVSPYWCEPLAPSARA, by selection with BS-I-B4 lectin [28]. These peptides, SSLRGF and NCVSPYWCEPLAPSARA, inhibited the agglutination of pig red blood cells (RBCs) by human serum. Two peptides, FHENWPS and FHEFWPT, that inhibit the agglutination of RBCs were identified by selection against anti-Gal antibody by Lang et al. [42]. However, the peptides identified from three selections contained no obvious consensus sequence.

Influenza virus hemagglutinin (HA) recognizes sialylgalactose structures (Neu5Ac-Gal) in glycoproteins and glycolipids on the cell surface in the initial stage of the infection process (Figure 4). Matsubara et al. identified CMPs from a pentadecapeptide library by selection with HAs of the H1 and H3 subtypes [17]. A HA-binding peptide, ARLSPTMVHPNGAQP, was identified from the first selection, and mutational sublibraries were prepared. A secondary selection was performed to improve the binding affinity for HAs, and the peptide was matured to peptide s2, ARLPRTMVHPKPAQP. The peptide was modified with a stearoyl group, and a molecular assembly of the alkylated peptides inhibited the infection of Madin-Darby canine kidney cells by influenza virus (Figure 3). Finally, a pentapeptide fragment from the N-terminal of s2, ARLPR [s2(1–5)], was found to show the highest inhibitory activity. A docking study of the interaction between the peptide s2(1–5) and HA suggested that the peptide is recognized by the Neu5Ac-Gal receptor-binding pocket (Figure 5(a)). The figure indicates that three side chains of H3HA (Ser 136, Asn137, and Glu190) have the potential to interact with the peptide instead of Neu5Ac, and hydrophobic residues (Leu194, Leu226, and Trp222) are close to the peptide (Figure 5(b)).

4. CMPs against Oligosaccharide-Binding Antibodies

4.1. Oligosaccharide-Mimetic Peptides for Inhibition

Glycoproteins and glycosphingolipids have unique oligosaccharide structures at their nonreducing termini [1]. Cell-cell communication is performed by oligosaccharides that are recognized by families of cell adhesion proteins such as selectins and sialic acid-binding immunoglobulin- (Ig-) like lectins (siglecs). Pathogenic viruses, toxins, and bacteria also recognize oligosaccharide structures [3]. Because an abundant variety of oligosaccharide structures relates to many carbohydrate-protein interactions, oligosaccharide-mimetic peptides mediate many kinds of inhibitory activities.

The sialyl- ( ) structure, Neu5Acα2-3Galβ1-4(Fucα1-3)GlcNAc, is recognized by E-selectin and is a famous carbohydrate antigen (Figure 4). -mimetic peptides were identified by selection against E-selectin [29, 30] and anti- antibody [36] (Tables 1 and 2). Martens et al. identified the HITWDQLWNVMN peptide and further optimized the sequence as DITWDQLWDLMK using a mutagenesis library [29]. The binding affinity of the synthetic peptide for E-selectin was improved 100-fold by this optimization (IC50 for binding to E-selectin; from 420 nM to 4 nM). The DITWDQLWDLMK peptide inhibited the adhesion of HL-60 cells and reduced neutrophil rolling on lipopolysaccharide- (LPS-) stimulated human umbilical vein endothelial cells. Qiu et al. designed WRY-containing peptides from the -mimetic peptide sequences, but these peptides cross-reacted with anti- antibody. Octameric multiple antigen peptides (MAPs) were conjugated with QS-21 adjuvant, which resulted in cytotoxic IgM and IgG antibodies (Figures 3 and 6). MAPs, in which peptides are attached to an octabranched amino acid backbone, are used to generate antibodies against a synthetic peptide, which is useful for the design of vaccines [94]. Katagihallimath et al. selected a cyclic CSRLNYLHC peptide against anti- antibody [37]. The trisaccharide structure is known as CD15 or SSEA-1, and this structure is expressed in the developing and adult murine central nervous system. The mimetic peptide inhibited CD24-induced neurite outgrowth.

Target antibodies
Name of antibodyPeptide libraryPeptide motif or representative sequences (peptide name)Carbohydrate antigenReferencesNotes*

Anti-LewisY (LeY) B3X8APWLYGPAFuc 1-2Gal 1-4(Fuc 1-3)GlcNAc[34, 35]Induction of anti-LeY immune responses
BR55-2; 15-6AX15WRY-containing peptide[36]Cross-reaction with anti-LeX
Anti-sialyl LewisX (sLeX)FH-6X15WRY-containing peptideNeu5Ac 2-3Gal 1-4(Fuc 1-3)GlcNAc[36]Cross-reaction with anti-LeY; octameric MAP-QS21
Anti-LewisX (LeX)L5X12, CX7CCSRLNYLHCGal 1-4(Fuc 1-3)GlcNAc[37]Inhibition of CD24-induced neurite outgrowth
Antilipooligosaccharide (LOS) X7SMYGSYN, APARQLPLOS of group B Neisseria meningitidis [38]Peptide-DT
Antilipooligosaccharide (LOS)X12NMMRFTSQPPNN and so forthLOS of nontypeable Haemophilus influenzae [39]Peptide-KLH
Anti- -1,2-oligomannosideDJ2.8X7FHENWPS -1,2-oligomannoside[40]Peptide-KLH
Anti-L2/HNK-1L2-412X15FLHTRLFVSDWYHTP, FLHTRLFVSO4-3GlcA 1-3Gal 1-4GlcNAc[41]Promotion of neurite outgrowth
Anti-Gal BX7, CX7CFHENWPS, FHEFWPTXenoreactive -Gal antigenic epitope[42]Inhibition of RBC agglutination
Anti-GMDPE6/1.2X15RVPPRYHAKISPMVNN-acetylglucosaminyl- 1,4-N-acetylmuramyl-alanyl-D-isoglutamine (GMDP)[43]Peptide-OVA
Antiglucitollysine 41; 226X12, CX9CCTSRXC motifGlc-Lys[44]Inhibition of Glu-Lys binding
Antihigh-mannose oligosaccharides2G12X15CXACPPSHVLDMRSGTCLAAEGK (2G12.1)Man9GlcNAc2 (HIV-1 gp120)[45]X-ray analysis (no structural mimic)

* DT: diphtheria toxoid; KLH: keyhole limpet hemocyanin; OVA: ovalbumin.

Neutral glycosphingolipid Lc4Cer-mimetic peptides showed unique activity [46] (Table 3). Lc4Cer contains Galβ1-3GlcNAcβ1-3Galβ1-4Glc tetrasaccharide that is linked to ceramide (Figure 4), and Jack bean β-galactosidase digests a nonreducing terminus β-Gal to give Lc3Cer. The Lc4Cer-mimetic peptides inhibited digestion by β-galactosidase at a high concentration of enzyme, whereas the peptides enhanced the digestion of Lc4Cer at lower concentration of enzyme. This unique activity of the peptides was also shown in the digestion of nLc4Cer. This group also identified WHW-containing peptides such as WHWRHRIPLQLAAGR by selection with anti-GD1α antibody [47]. The ganglioside GD1α is cell adhesion molecule of murine metastatic large cell lymphoma (RAW117-H10 cells) that binds to endothelial cells. GD1α-mimetic peptides inhibited the adhesion between RAW117-H10 cells and hepatic sinusoidal endothelial (HSE) cells. Furthermore, the metastasis of RAW117-H10 cells to lung and spleen was completely inhibited by the intravenous injection of the peptide. Subsequently, WHW was found to be a minimal sequence that mimics the GD1α structure [48]. To modify the liposome surface with the WHW peptide, the WHW tripeptide was conjugated to alkyl groups such as palmitoyl or stearoyl groups (Figure 3). Coating of liposomes with peptides is often performed in drug delivery systems. The WHW-modified liposomes inhibited the adhesion between RAW117-H10 cells and HSE cells.

Target antibodiesName of antibodyPeptide libraryPeptide motif or representative sequences (peptide name)Glycolipid structuresReferencesNotes*

Anti-Lc4Cer; anti-nLc4CerAD117m; H11X15VPPXFXXXYGal 1-3GlcNAc 1-3Gal 1-4Glc 1-1′Cer; Gal 1-4GlcNAc 1-3Gal 1-4Glc 1-1′Cer[46]Modulation of -galactosidase activity
Anti-GD1 KA17X15WHWRHRIPLQLAAGRNeu5Ac 2-3Gal 1-3(Neu5Ac 2-6)GalNAc 1-4Gal 1-4Glc 1-1′Cer[47, 48]Inhibition of metastasis; peptide-liposome
Anti-asialo GM1clone 10X7, CX7CKL/VWQXXXGal 1-3GalNAc 1-4Gal 1-4Glc 1-1′Cer[49](Phage ELISA only)
Anti-GD3/GD2ME36.1X15WRY-containing peptide
and so forth
Neu5Ac 2-8Neu5Ac 2-3Gal 1-4Glc 1-1′Cer; GalNAc 1-4(Neu5Ac 2-8Neu5Ac 2-3)Gal 1-4Glc 1-1′Cer[36, 50, 51]Octameric MAP-QS21/KLH
Anti-GD214.18CX10CCDGGWLSKGSWC; CGRLKMVPDLECGalNAc 1-4(Neu5Ac 2-8Neu5Ac 2-3)Gal 1-4Glc 1-1′Cer[5254]Docking study; peptide-KLH
14G2aX15EDPSHSLGLDVALFM[55, 56]Molecular modeling; DNA vaccine; induction of CD8+ T cell response
14G2aXCX8CXRCNPNMEPPRCF[57, 58]Inhibition of antibody binding to IMR-32 cells
Anti-GD34F6X15LAPPRPRSELVFLSV (GD3P4) Neu5Ac 2-8Neu5Ac 2-3Gal 1-4Glc 1-1′Cer[59]Peptide-VSSP
Anti-Gb3CerX12WHWTWLSEYGal 1-4Gal 1-4Glc 1-1′Cer[60]Neutralization of Shiga toxin
Anti-Neu5Gc-containing ganglioside (Neu5Gc-GM3)1E10; chimeric P3; 1E10X9, X12KPPR, RRPR/K; LEICSYTPDEGC; KCGHHYCRQVDLNeu5Gc 2-3Gal 1-4Glc 1-1′Cer[61, 62]Inhibition of 1E10 binding to P3
Anti-phenolic glycolipid-I (PGL-I)III603.8X7W(T/R)LGPY(V/M)Mycobacterium leprae-specific antigen[63]Does not bind to antibodies in serum

* MAP: multiple antigen peptide; VSSP: very small size proteoliposomes.

Tryptophan/tyrosine-containing tripeptides (YPY for ConA, WRY for , and WHW for GD1α) may comprise a key sequence that mimics oligosaccharide structure. Although Gb3 (Galα1-4Galβ1-4Glc trisaccharide) is dissimilar to the disaccharide (Galβ1-3GlcNAcβ) structure of Lc4 at the nonreducing terminus, Miura et al. identified a WHW-containing peptide (WHWTWLSEY) that mimics the Gb3 structure [60]. Gb3 is well known as a receptor for Shiga toxin (Stx). The Gb3-mimetic peptide showed neutralization activity against Stxs (Stx-1 and Stx-2) in a HeLa cell cytotoxicity assay. The binding affinity of the Gb3-mimetic peptide for Stx-1 was also investigated by surface plasmon resonance analysis ( = 1.4 nM).

4.2. Oligosaccharide-Mimetic Peptides for Vaccination

The immunogenicity of oligosaccharides is weak because oligosaccharides are ubiquitous components of cell membranes in tissues throughout the human body. When antioligosaccharide antibodies are generated, they attack these tissues and cause the risk of autoimmune disease. For example, lipopolysaccharides of Campylobacter jejuni isolated from GBS patients contain ganglioside-like epitopes such as GM1, GM1b, GD1a, and GalNAc-GDla, and these epitopes induce Guillain-Barre syndrome [95]. However, this low immunogenicity interferes with the preparation of antioligosaccharide antibodies that are useful for the investigation of glycoconjugate function.

To improve the binding affinity, specificity and cytotoxicity of antibodies, oligosaccharide-mimetic peptides are applied as peptide mimotopes of carbohydrate antigens for vaccination (Figure 6). Oligosaccharide-mimetic peptides were identified by selection against [34, 35, 37], [36, 50], GD2 [36, 5056], GD3 [36, 50, 59], lipooligosaccharide (LOS) [38, 39], β-1,2-oligomannoside [40], N-acetylglucosaminyl-β1,4-N-acetylmuramyl-alanyl-D-isoglutamine (GMDP) [43], and high-mannose oligosaccharide (Man9GlcNAc2 for HIV-1 gp120) [45]. The oligosaccharide-mimetic peptides were chemically synthesized and conjugated with adjuvant. To enhance the immunogenicity of the peptides, MAPs were prepared and resulted in dimeric, tetrameric, and octameric dendrimers (Figure 3). The peptide-adjuvant conjugates were vaccinated, with the adjuvants used being keyhole limpet hemocyanin (KLH) [39, 40, 53, 54], QS-21 [36, 50, 54], diphtheria toxoid (DT) [38], ovalbumin (OVA) [43], or very small size proteoliposomes (VSSP) [59] (Figure 6, Tables 2 and 3). In some cases, DNA vaccination was also performed [55, 56]. The CMP-induced antibodies are able to bind to peptide mimotopes and carbohydrate antigens.

5. CMPs against Polysaccharide-Binding Antibodies

Most polysaccharide-mimetic peptides to be applied for vaccination are identified as peptide mimotopes of carbohydrate antigens (Figure 6). Capsular polysaccharides of microorganisms are carbohydrate antigens, and it is known that these polysaccharides cause meningoencephalitis in immunocompromised patients, particularly those with AIDS (polysaccharide from Cryptococcus neoformans), pneumonia and bacteremia (Streptococcus pneumoniae), bacterial meningitis (Neisseria meningitidis), cholera (Vibrio cholerae), tuberculosis (Mycobacterium tuberculosis), and so forth (Table 4). These peptide mimotopes are potential antigens for safe vaccination and are expected to produce highly cytotoxic antibodies.

SpeciesCarbohydrate antigenName of antibodyPeptide libraryPeptide motif or representative sequences (peptide name)ReferencesNotes*

Polysaccharide (glucuronoxylomannan; GXM)2H1X6, X10, ADVA X6 TPXW [M/L][M/L] X6 AAG(E)TPXWM/LM/L, W/YXWM/LY; GLQYTPSWMLVG (PA1); SYSWMYE (P601E); FGGETFTPDWMMEVAIDNE (P206.1)[6467]Four motifs; X-ray analysis (PA1); peptide evolution (P206.1); peptide-KLH/TT
Streptococcus speciesCapsular polysaccharide (type 3, group B) S9X9WENWMMGNA; FDTGAFDPDWPA[68]Group B streptococci (GBS); peptide-KLH/BSA/OVA
Capsular polysaccharide (serotype 4)mAb4X15SGQARVLYSEFINAL (pep4)[69]DNA vaccine
(serotype 8)(human mAb IgA)X12FHLPYNHNWFAL (PUB1)[70]Peptide-TT
(serotype 6B, 9V)206; F-5; Db3G9X12, X15MP7, 12, 55, 58[71]Peptide-KLH
Streptococcus  pyogenesCell-wall polysaccharide (group A)SA-3; Strep9; HGAC39; HGAC47; HGAC101X6, XCX8CX, X8CX8, X15CX, X15DRPVPY[72]Basis of peptide-carbohydrate cross-reactivity
Streptococcus agalactiae(serotype A, B, C)(IgG2, Ig polyclonal)X12NPDHPRVPTFMA (2–8); LIPFHKHPHHRG (3-2)[73]DNA vaccine; MAP-CFA/IFA
Neisseria meningitidisCapsular polysaccharide (serogroup A)9C10X15GEASGLCCRWSSLKGC[74]Peptide-proteasome
(serogroup B)HmenB3X12NKVIWDRDWMYP[75]Peptide-BSA-CFA/IFA
(serogroup B)9-2-L3, 7, 9CX6C, CX9CCGAVIDDC[76]Peptide-KLH
(serogroup B) [poly- 2–8 sialic acid (PSA)]30H12CX9CCSSVTAWTTGCG[77, 78]Enhanced migration of grafted neuroblasts in mouse brain
(serogroup B)Seam3X9, X12DYAWDQTHQDPAK (9M)[79]Peptide-KLH, DNA vaccine
(serogroup B)13D9X15RGDKSRPPVWYVEGE[80]Phage vaccine
(serogroups B and C) (IgG2, Ig polyclonal)X12EQEIFTNITDRV (G3)[73]DNA vaccine; MAP-CFA/IFA
(serogroup C)1E4X15GFSYYRPPWIL (Pep2C)[81]Peptide-proteasome
[N-propionyl derivative of CPS] [82]
Vibrio choleraeCapsular polysaccharide (serogroup O139)Vc1; Vc2; ICL12six libraries (X9, X12, X28 etc.)AEGEFSPGVWKAAFQGDKLPDPAK and so forth[83]Peptide-KLH/BSA
(serogroup O1) Ogawa serotypeS-20-4; A-20-6X12, X7, CX7CNHNYPPLSLLTF (4P-8)[84]Peptide-KLH/BSA; docking study
(serogroup O1) Ogawa and Inab serotypes72.1X12, X7, CX7CECLLLSKYCMPS (3ME-1); SMCMHGGAYCFP (3ME-2)[85]Peptide-KLH/BSA-CFA/IFA
Shigella flexneriO-antigen of lipopolysaccharide (serotype 5a)mIgAs C5; I3X9YKPLGALTH; KVPPWARTA[86]Phage vaccine
(serotype 2a) F22-4X12YLEDWIKYNNQK (B1)[19]X-ray analysis
Melanoma-associated chondroitin sulfate proteoglycan (MCSP)763.74X6VHINAH[87]Inhibition of MCSP binding
Entamoeba histolyticaGPI-linked proteophosphoglycan antigensEH5six libraries (X9, X12, X28 etc.)GTHPXL[88]Glycosylphosphatidylinositol (GPI); phage vaccine
Mycobacterium tuberculosisNeutral polysaccharidesX12QEPLMGTVPIRAGGGS (P1)[89]Peptide oligomer vaccine
Mycobacterium tuberculosisMannosylated lipoarabinomannanCS40X12ISLTEWSMWYRH (B11)[90]Peptide-KLH-adjuvants
Burkholderia pseudomalleiExopolysaccharide (EPS)3VIE5; 4VA5X12, X7, CX7CCYLPFQLSC; CHPLFDARC[91]Peptide-thyroglobulin
Brucella melitensis; Brucella abortus Lipopolysaccharide4F9; 11B2X9, X12,
CX9CX, X15
Staphylococcus aureusPeptidoglycanX12Sp-31[93]MAP vaccine

* BSA: bovine serum albumin; TT: tetanus toxoid; CFA: complete Freund’s adjuvant; IFA: incomplete Freund’s adjuvant.

The typical methodology for vaccination uses a CMP-conjugated adjuvant. Valadon et al. identified CMPs that bind to anticryptococcal polysaccharide (glucuronoxylomannan, GXM) monoclonal antibody 2H1 [64]. The CMPs shared four motifs, for example, (E)TPXWM/LM/L and W/YXWM/LYE, and the dodecapeptide, GLQYTPSWMLVG (PA1) was found to bind 2H1 with a of 295 nM [64]. The three-dimensional structure of 2H1 has been solved in a complex with PA1 [65]. The peptide PA1 was improved by selection from a PA1-based sublibrary, which identified the peptide P206-1 (FGGETFTPDWMMEVAIDNE) [66]. The affinity of peptide 206-1 for 2H1 was 80-fold higher than that of PA1 ( of 3.7 nM). Immunization of mice with P206-1-tetanus toxoid (TT), but not PA1 or P601E (DGASYSWMYEA), induced an anti-GXM response [66, 67].

Although antibodies against the capsular polysaccharide of the same species (e.g., Neisseria meningitidis serogroup B) were used, the CMPs identified were different and shared no consensus motif [73, 7580] (Table 4). This may be due to the different antibodies used (HmenB3, 9-2-L3, 30H12, Seam3, or 13D9), different primary peptide libraries (CX6C, X9, CX9C, X12, or X15), or different selection conditions. Harris et al. also concluded that the CMPs identified by each antibody possessed distinct consensus motifs [72]. A variety of peptide-conjugating adjuvants such as KLH, TT, BSA, OVA, proteasome, and thyroglobulin have been used. In some cases, phage particles were directly used for vaccination [80, 86, 88], and a high level of the subtype in the response against CMPs was shown [80].

Theillet et al. clarified the structural mimicry of O-antigen oligosaccharide by CMPs [19]. Figure 5(c) shows a structural representation of the antibody-peptide complex in which the sugar chains were replaced by amino acids. Glc and GlcNAc were replaced by Tyr or Asp, and one or more hydrogen bonds are indicated. On the other hand, high-mannose oligosaccharide-mimic peptide (2G12-1 peptide) binds to a neighboring pocket of the oligosaccharide (Table 2) [45]. The binding site for the DVFYPYPYASGS peptide, which was selected against ConA, was different from the mannose/trimannose-binding site [26]. However, the peptide inhibits α-mannopyranoside binding to ConA [25], indicating that this peptide shows functional mimicry rather than structural mimicry.

6. Conclusion

Anticarbohydrate antibodies are necessary for clarifying the biological functions of carbohydrates, the detection of carbohydrates during etiological diagnosis, and therapy for carbohydrate-related diseases [7, 96]. Due to the difficulty in obtaining homogeneous glycoconjugates and carbohydrate-binding proteins, phage display libraries have been applied for the identification of peptide mimotopes. In this paper, the selection of CMPs was classified according to the types of target carbohydrates. The first selection was performed against lectins, and then the selections were performed against anticarbohydrate antibodies. To apply the peptide mimotopes for vaccination, this methodology is becoming more widespread.


The preparation of this paper was supported in part by the Keio Gijuku Fukuzawa Memorial Fund for the Advancement of Education and Research.


  1. A. Varki, “Biological roles of oligosaccharides: all of the theories are correct,” Glycobiology, vol. 3, no. 2, pp. 97–130, 1993. View at: Google Scholar
  2. K. Takahashi, K. Tanabe, M. Ohnuki et al., “Induction of pluripotent stem cells from adult human fibroblasts by defined factors,” Cell, vol. 131, no. 5, pp. 861–872, 2007. View at: Publisher Site | Google Scholar
  3. H. Lis and N. Sharon, “Lectins: carbohydrate-specific proteins that mediate cellular recognition,” Chemical Reviews, vol. 98, no. 2, pp. 637–674, 1998. View at: Google Scholar
  4. W. I. Weis and K. Drickamer, “Structural basis of lectin-carbohydrate recognition,” Annual Review of Biochemistry, vol. 65, pp. 441–473, 1996. View at: Google Scholar
  5. G. A. Nores, R. D. Lardone, R. Comín, M. E. Alaniz, A. L. Moyano, and F. J. Irazoqui, “Anti-GM1 antibodies as a model of the immune response to self-glycans,” Biochimica et Biophysica Acta, vol. 1780, no. 3, pp. 538–545, 2008. View at: Publisher Site | Google Scholar
  6. S. F. Slovin, S. J. Keding, and G. Ragupathi, “Carbohydrate vaccines as immunotherapy for cancer,” Immunology and Cell Biology, vol. 83, no. 4, pp. 418–428, 2005. View at: Publisher Site | Google Scholar
  7. R. Kannagi and S. Hakomori, “A guide to monoclonal antibodies directed to glycotopes,” Advances in Experimental Medicine and Biology, vol. 491, pp. 587–630, 2001. View at: Google Scholar
  8. C.-H. Hsu, S.-C. Hung, C.-Y. Wu, and C.-H. Wong, “Toward automated oligosaccharide synthesis,” Angewandte Chemie, vol. 50, no. 50, pp. 11872–11923, 2011. View at: Publisher Site | Google Scholar
  9. T. J. Boltje, T. Buskas, and G. J. Boons, “Opportunities and challenges in synthetic oligosaccharide and glycoconjugate research,” Nature Chemistry, vol. 1, no. 8, pp. 611–622, 2009. View at: Publisher Site | Google Scholar
  10. S. I. Nishimura, “Combinatorial syntheses of sugar derivatives,” Current Opinion in Chemical Biology, vol. 5, no. 3, pp. 325–335, 2001. View at: Publisher Site | Google Scholar
  11. S. M. Hancock, M. D. Vaughan, and S. G. Withers, “Engineering of glycosidases and glycosyltransferases,” Current Opinion in Chemical Biology, vol. 10, no. 5, pp. 509–519, 2006. View at: Publisher Site | Google Scholar
  12. A. M. Daines, B. A. Maltman, and S. L. Flitsch, “Synthesis and modifications of carbohydrates, using biotransformations,” Current Opinion in Chemical Biology, vol. 8, no. 2, pp. 106–113, 2004. View at: Publisher Site | Google Scholar
  13. J. K. Scott, D. Loganathan, R. B. Easley, X. Gong, and I. J. Goldstein, “A family of concanavalin A-binding peptides from a hexapeptide epitope library,” Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 12, pp. 5398–5402, 1992. View at: Publisher Site | Google Scholar
  14. M. N. Fukuda, “Peptide-displaying phage technology in glycobiology,” Glycobiology, vol. 22, no. 3, pp. 318–325, 2012. View at: Publisher Site | Google Scholar
  15. F. C. Dudak, I. H. Boyaci, and B. P. Orner, “The discovery of small-molecule mimicking peptides through phage display,” Molecules, vol. 16, no. 1, pp. 774–789, 2011. View at: Publisher Site | Google Scholar
  16. R. Cortese, F. Felici, G. Galfre, A. Luzzago, P. Monaci, and A. Nicosia, “Epitope discovery using peptide libraries displayed on phage,” Trends in Biotechnology, vol. 12, no. 7, pp. 262–267, 1994. View at: Publisher Site | Google Scholar
  17. T. Matsubara, A. Onishi, T. Saito et al., “Sialic acid-mimic peptides as hemagglutinin inhibitors for anti-influenza therapy,” Journal of Medicinal Chemistry, vol. 53, no. 11, pp. 4441–4449, 2010. View at: Publisher Site | Google Scholar
  18. N. K. Sauter, J. E. Hanson, G. D. Glick et al., “Binding of influenza virus hemagglutinin to analogs of its cell-surface receptor, sialic acid: analysis by proton nuclear magnetic resonance spectroscopy and X-ray crystallography,” Biochemistry, vol. 31, no. 40, pp. 9609–9621, 1992. View at: Publisher Site | Google Scholar
  19. F. X. Theillet, F. A. Saul, B. Vulliez-Le Normand et al., “Structural mimicry of O-antigen by a peptide revealed in a complex with an antibody raised against Shigella flexneri serotype 2a,” Journal of Molecular Biology, vol. 388, no. 4, pp. 839–850, 2009. View at: Publisher Site | Google Scholar
  20. G. P. Smith and V. A. Petrenko, “Phage display,” Chemical Reviews, vol. 97, no. 2, pp. 391–410, 1997. View at: Google Scholar
  21. G. P. Smith, “Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface,” Science, vol. 228, no. 4705, pp. 1315–1317, 1985. View at: Google Scholar
  22. J. K. Scott and G. P. Smith, “Searching for peptide ligands with an epitope library,” Science, vol. 249, no. 4967, pp. 386–390, 1990. View at: Google Scholar
  23. B. Ru, J. Huang, P. Dai et al., “MimoDB: a new repository for mimotope data derived from phage display technology,” Molecules, vol. 15, no. 11, pp. 8279–8288, 2010. View at: Publisher Site | Google Scholar
  24. J. Huang, B. Ru, P. Zhu et al., “MimoDB 2.0: a mimotope database and beyond,” Nucleic Acids Research, vol. 40, no. D1, pp. D271–D277, 2012. View at: Publisher Site | Google Scholar
  25. K. R. Oldenburg, D. Loganathan, I. J. Goldstein, P. G. Schultz, and M. A. Gallop, “Peptide ligands for a sugar-binding protein isolated from a random peptide library,” Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 12, pp. 5393–5397, 1992. View at: Publisher Site | Google Scholar
  26. D. Jain, K. Kaur, B. Sundaravadivel, and D. M. Salunke, “Structural and functional consequences of peptide-carbohydrate mimicry: crystal structure of a carbohydrate-mimicking peptide bound to concanavalin A,” Journal of Biological Chemistry, vol. 275, no. 21, pp. 16098–16102, 2000. View at: Publisher Site | Google Scholar
  27. D. L. Kooyman, S. B. Mcclellan, W. Parker et al., “Identification and characterization of a galactosyl peptide mimetic. Implications for use in removing xenoreactive anti-a gal antibodies,” Transplantation, vol. 61, no. 6, pp. 851–855, 1996. View at: Google Scholar
  28. J. Zhan, Z. Xia, L. Xu, Z. Yan, and K. Wang, “A peptide mimetic of Gal-α1,3-Gal is able to block human natural antibodies,” Biochemical and Biophysical Research Communications, vol. 308, no. 1, pp. 19–22, 2003. View at: Publisher Site | Google Scholar
  29. C. L. Martens, S. E. Cwirla, R. Y. W. Lee et al., “Peptides which bind to E-selectin and block neutrophil adhesion,” Journal of Biological Chemistry, vol. 270, no. 36, pp. 21129–21136, 1995. View at: Publisher Site | Google Scholar
  30. M. N. Fukuda, C. Ohyama, K. Lowitz et al., “A peptide mimic of E-selectin ligand inhibits sialyl Lewis X-dependent lung colonization of tumor cells,” Cancer Research, vol. 60, no. 2, pp. 450–456, 2000. View at: Google Scholar
  31. L. Yu, P. S. Yu, E. Yee Yen Mui et al., “Phage display screening against a set of targets to establish peptide-based sugar mimetics and molecular docking to predict binding site,” Bioorganic and Medicinal Chemistry, vol. 17, no. 13, pp. 4825–4832, 2009. View at: Publisher Site | Google Scholar
  32. L. L. Eggink and J. K. Hoober, “A biologically active peptide mimetic of N-acetylgalactosamine/galactose,” BMC Research Notes, vol. 2, article 23, 2009. View at: Publisher Site | Google Scholar
  33. Z. Xu, G. S. Qian, Q. Li, Q. J. Feng, G. M. Wu, and K. L. Li, “Screening of mimetic peptides for CD14 binding site with LBP and antiendotoxin activity of mimetic peptide in vivo and in vitro,” Inflammation Research, vol. 58, no. 1, pp. 45–53, 2009. View at: Publisher Site | Google Scholar
  34. R. Hoess, U. Brinkmann, T. Handel, and I. Pastan, “Identification of a peptide which binds to the carbohydrate-specific monoclonal antibody B3,” Gene, vol. 128, no. 1, pp. 43–49, 1993. View at: Publisher Site | Google Scholar
  35. Q. Lou and I. Pastan, “A Lewis(y) epitope mimicking peptide induces anti-Lewis(y) immune responses in rabbits and mice,” Journal of Peptide Research, vol. 53, no. 3, pp. 252–260, 1999. View at: Publisher Site | Google Scholar
  36. J. Qiu, P. Luo, K. Wasmund, Z. Steplewski, and T. Kieber-Emmons, “Towards the development of peptide mimotopes of carbohydrate antigens as cancer vaccines,” Hybridoma, vol. 18, no. 1, pp. 103–112, 1999. View at: Google Scholar
  37. N. Katagihallimath, A. Mehanna, D. Guseva, R. Kleene, and M. Schachner, “Identification and validation of a Lewisx glycomimetic peptide,” European Journal of Cell Biology, vol. 89, no. 1, pp. 77–86, 2010. View at: Publisher Site | Google Scholar
  38. B. M. Charalambous and I. M. Feavers, “Peptide mimics elicit antibody responses against the outer-membrane lipooligosaccharide of group B Neisseria meningitidis,” FEMS Microbiology Letters, vol. 191, no. 1, pp. 45–50, 2000. View at: Publisher Site | Google Scholar
  39. Y. Hou and X. X. Gu, “Development of peptide mimotopes of lipooligosaccharide from nontypeable Haemophilus influenzae as vaccine candidates,” Journal of Immunology, vol. 170, no. 8, pp. 4373–4379, 2003. View at: Google Scholar
  40. T. Jouault, C. Fradin, F. Dzierszinski et al., “Peptides that mimic Candida albicans-derived β-1,2-linked mannosides,” Glycobiology, vol. 11, no. 8, pp. 693–701, 2001. View at: Google Scholar
  41. M. Simon-Haldi, N. Mantei, J. Franke, H. Voshol, and M. Schachner, “Identification of a peptide mimic of the L2/HNK-1 carbohydrate epitope,” Journal of Neurochemistry, vol. 83, no. 6, pp. 1380–1388, 2002. View at: Publisher Site | Google Scholar
  42. J. Lang, J. Zhan, L. Xu, and Z. Yan, “Identification of peptide mimetics of xenoreactive α-Gal antigenic epitope by phage display,” Biochemical and Biophysical Research Communications, vol. 344, no. 1, pp. 214–220, 2006. View at: Publisher Site | Google Scholar
  43. A. G. Laman, A. O. Shepelyakovskaya, I. A. Berezin et al., “Identification of pentadecapeptide mimicking muramyl peptide,” Vaccine, vol. 25, no. 15, pp. 2900–2906, 2007. View at: Publisher Site | Google Scholar
  44. G. Rojas, A. Pupo, M. Del Rosario Aleman, and N. Santiago Vispo, “Preferential selection of Cys-constrained peptides from a random phage-displayed library by anti-glucitollysine antibodies,” Journal of Peptide Science, vol. 14, no. 11, pp. 1216–1221, 2008. View at: Publisher Site | Google Scholar
  45. A. Menendez, D. A. Calarese, R. L. Stanfield et al., “A peptide inhibitor of HIV-1 neutralizing antibody 2G12 is not a structural mimic of the natural carbohydrate epitope on gp120,” FASEB Journal, vol. 22, no. 5, pp. 1380–1392, 2008. View at: Publisher Site | Google Scholar
  46. T. Taki, D. Ishikawa, H. Hamasaki, and S. Handa, “Preparation of peptides which mimic glycosphingolipids by using phage peptide library and their modulation on β-galactosidase activity,” FEBS Letters, vol. 418, no. 1-2, pp. 219–223, 1997. View at: Publisher Site | Google Scholar
  47. D. Ishikawa, H. Kikkawa, K. Ogino, Y. Hirabayashi, N. Oku, and T. Taki, “GD1α-replica peptides functionally mimic GD1α, an adhesion molecule of metastatic tumor cells, and suppress the tumor metastasis,” FEBS Letters, vol. 441, no. 1, pp. 20–24, 1998. View at: Publisher Site | Google Scholar
  48. M. Takikawa, H. Kikkawa, T. Asai et al., “Suppression of GD1α ganglioside-mediated tumor metastasis by liposomalized WHW-peptide,” FEBS Letters, vol. 466, no. 2-3, pp. 381–384, 2000. View at: Publisher Site | Google Scholar
  49. J. X. Qiu and D. M. Marcus, “Use of peptide ligands to analyze the fine specificity of antibodies against asialo GM1,” Journal of Neuroimmunology, vol. 100, no. 1-2, pp. 58–63, 1999. View at: Publisher Site | Google Scholar
  50. T. Kieber-Emmons, P. Luo, J. Qiu, T. Y. Chang, M. Blaszczyk-Thurin, and Z. Steplewski, “Vaccination with carbohydrate peptide mimotopes promotes anti-tumor responses,” Nature Biotechnology, vol. 17, no. 7, pp. 660–665, 1999. View at: Publisher Site | Google Scholar
  51. A. Wondimu, T. Zhang, T. Kieber-Emmons et al., “Peptides mimicking GD2 ganglioside elicit cellular, humoral and tumor-protective immune responses in mice,” Cancer Immunology, Immunotherapy, vol. 57, no. 7, pp. 1079–1089, 2008. View at: Publisher Site | Google Scholar
  52. E. Förster-Waldl, A. B. Riemer, A. K. Dehof et al., “Isolation and structural analysis of peptide mimotopes for the disialoganglioside GD2, a neuroblastoma tumor antigen,” Molecular Immunology, vol. 42, no. 3, pp. 319–325, 2005. View at: Publisher Site | Google Scholar
  53. A. B. Riemer, E. Förster-Waldl, K. H. Brämswig et al., “Induction of IgG antibodies against the GD2 carbohydrate tumor antigen by vaccination with peptide mimotopes,” European Journal of Immunology, vol. 36, no. 5, pp. 1267–1274, 2006. View at: Publisher Site | Google Scholar
  54. M. Bleeke, S. Fest, N. Huebener et al., “Systematic amino acid substitutions improved efficiency of GD2-peptide mimotope vaccination against neuroblastoma,” European Journal of Cancer, vol. 45, no. 16, pp. 2915–2921, 2009. View at: Publisher Site | Google Scholar
  55. E. Bolesta, A. Kowalczyk, A. Wierzbicki et al., “DNA vaccine expressing the mimotope of GD2 ganglioside induces protective GD2 cross-reactive antibody responses,” Cancer Research, vol. 65, no. 8, pp. 3410–3418, 2005. View at: Google Scholar
  56. A. Wierzbicki, M. Gil, M. Ciesielski et al., “Immunization with a mimotope of GD2 ganglioside induces CD8+ T cells that recognize cell adhesion molecules on tumor cells,” Journal of Immunology, vol. 181, no. 9, pp. 6644–6653, 2008. View at: Google Scholar
  57. I. Horwacik, D. Czaplicki, K. Talarek et al., “Selection of novel peptide mimics of the GD2 ganglioside from a constrained phage-displayed peptide library,” International Journal of Molecular Medicine, vol. 19, no. 5, pp. 829–839, 2007. View at: Google Scholar
  58. I. Horwacik, M. Kurciński, M. Bzowska et al., “Analysis and optimization of interactions between peptides mimicking the GD2 ganglioside and the monoclonal antibody 14G2a,” International Journal of Molecular Medicine, vol. 28, no. 1, pp. 47–57, 2011. View at: Publisher Site | Google Scholar
  59. I. Popa, D. Ishikawa, M. Tanaka, K. Ogino, J. Portoukalian, and T. Taki, “GD3-replica peptides selected from a phage peptide library induce a GD3 ganglioside antibody response,” FEBS Letters, vol. 580, no. 5, pp. 1398–1404, 2006. View at: Publisher Site | Google Scholar
  60. Y. Miura, A. Sakaki, M. Kamihira, S. Iijima, and K. Kobayashi, “A globotriaosylceramide (Gb3Cer) mimic peptide isolated from phage display library expressed strong neutralization to Shiga toxins,” Biochimica et Biophysica Acta, vol. 1760, no. 6, pp. 883–889, 2006. View at: Publisher Site | Google Scholar
  61. A. Perez, E. S. Mier, N. S. Vispo, A. M. Vazquez, and R. P. Rodríguez, “A monoclonal antibody against NeuGc-containing gangliosides contains a regulatory idiotope involved in the interaction with B and T cells,” Molecular Immunology, vol. 39, no. 1-2, pp. 103–112, 2002. View at: Publisher Site | Google Scholar
  62. A. López-Requena, C. M. De Acosta, E. Moreno et al., “Gangliosides, Ab1 and Ab2 antibodies. I. Towards a molecular dissection of an idiotype-anti-idiotype system,” Molecular Immunology, vol. 44, no. 4, pp. 423–433, 2007. View at: Publisher Site | Google Scholar
  63. J. H. Youn, H. J. Myung, A. Liav et al., “Production and characterization of peptide mimotopes of phenolic glycolipid-I of Mycobacterium leprae,” FEMS Immunology and Medical Microbiology, vol. 41, no. 1, pp. 51–57, 2004. View at: Publisher Site | Google Scholar
  64. P. Valadon, G. Nussbaum, L. F. Boyd, D. H. Margulies, and M. D. Scharff, “Peptide libraries define the fine specificity of anti-polysaccharide antibodies to Cryptococcus neoformans,” Journal of Molecular Biology, vol. 261, no. 1, pp. 11–22, 1996. View at: Publisher Site | Google Scholar
  65. A. C. M. Young, P. Valadon, A. Casadevall, M. D. Scharff, and J. C. Sacchettini, “The three-dimensional structures of a polysaccharide binding antibody to Cryptococcus neoformans and its complex with a peptide from a phage display library: implications for the identification of peptide mimotopes,” Journal of Molecular Biology, vol. 274, no. 4, pp. 622–634, 1997. View at: Publisher Site | Google Scholar
  66. D. O. Beenhouwer, R. J. May, P. Valadon, and M. D. Scharff, “High affinity mimotope of the polysaccharide capsule of Cryptococcus neoformans identified from an evolutionary phage peptide library,” Journal of Immunology, vol. 169, no. 12, pp. 6992–6999, 2002. View at: Google Scholar
  67. P. Valadon, G. Nussbaum, J. Oh, and M. D. Scharff, “Aspects of antigen mimicry revealed by immunization with a peptide mimetic of Cryptococcus neoformans polysaccharide,” Journal of Immunology, vol. 161, no. 4, pp. 1829–1836, 1998. View at: Google Scholar
  68. S. H. Pincus, M. J. Smith, H. J. Jennings, J. B. Burritt, and P. M. Glee, “Peptides that mimic the group B streptococcal type III capsular polysaccharide antigen,” Journal of Immunology, vol. 160, no. 1, pp. 293–298, 1998. View at: Google Scholar
  69. G. B. Lesinski, S. L. Smithson, N. Srivastava, D. Chen, G. Widera, and M. A. J. Westerink, “A DNA vaccine encoding a peptide mimic of Streptococcus pneumoniae serotype 4 capsular polysaccharide induces specific anti-carbohydrate antibodies in Balb/c mice,” Vaccine, vol. 19, no. 13-14, pp. 1717–1726, 2001. View at: Publisher Site | Google Scholar
  70. U. K. Buchwald, A. Lees, M. Steinitz, and L. A. Pirofski, “A peptide mimotope of type 8 pneumococcal capsular polysaccharide induces a protective immune response in mice,” Infection and Immunity, vol. 73, no. 1, pp. 325–333, 2005. View at: Publisher Site | Google Scholar
  71. C. M. Smith, C. L. Passo, A. Scuderi et al., “Peptide mimics of two pneumococcal capsular polysaccharide serotypes (6B and 9V) protect mice from a lethal challenge with Streptococcus pneumoniae,” European Journal of Immunology, vol. 39, no. 6, pp. 1527–1535, 2009. View at: Publisher Site | Google Scholar
  72. S. L. Harris, L. Craig, J. S. Mehroke et al., “Exploring the basis of peptide-carbohydrate crossreactivity: evidence for discrimination by peptides between closely related anti-carbohydrate antibodies,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 6, pp. 2454–2459, 1997. View at: Publisher Site | Google Scholar
  73. Y. Wu, Q. Zhang, D. Sales, A. E. Bianco, and A. Craig, “Vaccination with peptide mimotopes produces antibodies recognizing bacterial capsular polysaccharides,” Vaccine, vol. 28, no. 39, pp. 6425–6435, 2010. View at: Publisher Site | Google Scholar
  74. M. C. Grothaus, N. Srivastava, S. L. Smithson et al., “Selection of an immunogenic peptide mimic of the capsular polysaccharide of Neisseria meningitidis serogroup A using a peptide display library,” Vaccine, vol. 18, no. 13, pp. 1253–1263, 2000. View at: Publisher Site | Google Scholar
  75. I. Park, I. H. Choi, S. J. Kim, and J. S. Shin, “Peptide mimotopes of Neisseria meningitidis group B capsular polysaccharide,” Yonsei Medical Journal, vol. 45, no. 4, pp. 755–758, 2004. View at: Google Scholar
  76. V. Lauvrak, G. Berntzen, U. Heggelund et al., “Selection and characterization of cyclic peptides that bind to a monoclonal antibody against meningococcal L3,7,9 lipopolysaccharides,” Scandinavian Journal of Immunology, vol. 59, no. 4, pp. 373–384, 2004. View at: Publisher Site | Google Scholar
  77. P. Torregrossa, L. Buhl, M. Bancila et al., “Selection of poly-α 2,8-sialic acid mimotopes from a random phage peptide library and analysis of their bioactivity,” Journal of Biological Chemistry, vol. 279, no. 29, pp. 30707–30714, 2004. View at: Publisher Site | Google Scholar
  78. P. Marino, J. C. Norreel, M. Schachner, G. Rougon, and M. C. Amoureux, “A polysialic acid mimetic peptide promotes functional recovery in a mouse model of spinal cord injury,” Experimental Neurology, vol. 219, no. 1, pp. 163–174, 2009. View at: Publisher Site | Google Scholar
  79. C. Lo Passo, A. Romeo, I. Pernice et al., “Peptide mimics of the group B meningococcal capsule induce bactericidal and protective antibodies after immunization,” Journal of Immunology, vol. 178, no. 7, pp. 4417–4423, 2007. View at: Google Scholar
  80. T. Menéndez, N. F. Santiago-Vispo, Y. Cruz-Leal et al., “Identification and characterization of phage-displayed peptide mimetics of Neisseria meningitidis serogroup B capsular polysaccharide,” International Journal of Medical Microbiology, vol. 301, no. 1, pp. 16–25, 2011. View at: Publisher Site | Google Scholar
  81. D. M. Prinz, S. L. Smithson, and M. A. J. Westerink, “Two different methods result in the selection of peptides that induce a protective antibody response to Neisseria meningitidis serogroup C,” Journal of Immunological Methods, vol. 285, no. 1, pp. 1–14, 2004. View at: Publisher Site | Google Scholar
  82. G. R. Moe and D. M. Granoff, “Molecular mimetics of Neisseria meningitidis serogroup B polysaccharide,” International Reviews of Immunology, vol. 20, no. 2, pp. 201–220, 2001. View at: Google Scholar
  83. S. Falklind-Jerkérus, F. Felici, C. Cavalieri et al., “Peptides mimicking Vibrio cholerae O139 capsular polysaccharide elicit protective antibody response,” Microbes and Infection, vol. 7, no. 15, pp. 1453–1460, 2005. View at: Publisher Site | Google Scholar
  84. M. N. Dharmasena, D. A. Jewell, and R. K. Taylor, “Development of peptide mimics of a protective epitope of Vibrio cholerae Ogawa O-antigen and investigation of the structural basis of peptide mimicry,” Journal of Biological Chemistry, vol. 282, no. 46, pp. 33805–33816, 2007. View at: Publisher Site | Google Scholar
  85. M. N. Dharmasena, S. J. Krebs, and R. K. Taylor, “Characterization of a novel protective monoclonal antibody that recognizes an epitope common to Vibrio cholerae Ogawa and Inaba serotypes,” Microbiology, vol. 155, no. 7, pp. 2353–2364, 2009. View at: Publisher Site | Google Scholar
  86. A. Phalipon, A. Folgori, J. Arondel et al., “Induction of anti-carbohydrate antibodies by phage library-selected peptide mimics,” European Journal of Immunology, vol. 27, no. 10, pp. 2620–2625, 1997. View at: Publisher Site | Google Scholar
  87. M. Geiser, D. Schultz, A. Le Cardinal, H. Voshol, and C. García-Echeverría, “Identification of the human melanoma-associated chondroitin sulfate proteoglycan antigen epitope recognized by the antitumor monoclonal antibody 763.74 from a peptide phage library,” Cancer Research, vol. 59, no. 4, pp. 905–910, 1999. View at: Google Scholar
  88. H. Melzer, P. Fortugno, E. Mansouri et al., “Antigenicity and immunogenicity of phage library-selected peptide mimics of the major surface proteophosphoglycan antigens of Entamoeba histolytica,” Parasite Immunology, vol. 24, no. 6, pp. 321–328, 2002. View at: Publisher Site | Google Scholar
  89. G. Gevorkian, E. Segura, G. Acero et al., “Peptide mimotopes of Mycobacterium tubercolosis carbohydrate immunodeterminants,” Biochemical Journal, vol. 387, no. 2, pp. 411–417, 2005. View at: Publisher Site | Google Scholar
  90. A. Barenholz, A. H. Hovav, Y. Fishman, G. Rahav, J. M. Gershoni, and H. Bercovier, “A peptide mimetic of the mycobacterial mannosylated lipoarabinomannan: characterization and potential applications,” Journal of Medical Microbiology, vol. 56, no. 5, pp. 579–586, 2007. View at: Publisher Site | Google Scholar
  91. J. B. Legutki, M. Nelson, R. Titball, D. R. Galloway, A. Mateczun, and L. W. Baillie, “Analysis of peptide mimotopes of Burkholderia pseudomallei exopolysaccharide,” Vaccine, vol. 25, no. 45, pp. 7796–7805, 2007. View at: Publisher Site | Google Scholar
  92. C. Beninati, M. Garibaldi, C. L. Passo et al., “Immunogenic mimics of Brucella lipopolysaccharide epitopes,” Peptides, vol. 30, no. 10, pp. 1936–1939, 2009. View at: Publisher Site | Google Scholar
  93. Y. Chen, B. Liu, D. Yang et al., “Peptide mimics of peptidoglycan are vaccine candidates and protect mice from infection with Staphylococcus aureus,” Journal of Medical Microbiology, vol. 60, no. 7, pp. 995–1002, 2011. View at: Publisher Site | Google Scholar
  94. J. P. Tam, “Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system,” Proceedings of the National Academy of Sciences of the United States of America, vol. 85, no. 15, pp. 5409–5413, 1988. View at: Google Scholar
  95. N. Yuki, “Infectious origins of, and molecular mimicry in, Guillain-Barré and Fisher syndromes,” Lancet Infectious Diseases, vol. 1, no. 1, pp. 29–37, 2001. View at: Publisher Site | Google Scholar
  96. T. Feizi, “Demonstration by monoclonal antibodies that carbohydrate structures of glycoproteins and glycolipids are onco-developmental antigens,” Nature, vol. 314, no. 6006, pp. 53–57, 1985. View at: Google Scholar

Copyright © 2012 Teruhiko Matsubara. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

3555 Views | 1715 Downloads | 21 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder